Free Trial

Centene (CNC) Stock Forecast & Price Target

Centene logo
$31.42 -1.10 (-3.38%)
Closing price 07/11/2025 03:59 PM Eastern
Extended Trading
$31.40 -0.02 (-0.06%)
As of 07/11/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Centene - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
12
Buy
6

Based on 18 Wall Street analysts who have issued ratings for Centene in the last 12 months, the stock has a consensus rating of "Hold." Out of the 18 analysts, 12 have given a hold rating, and 6 have given a buy rating for CNC.

Consensus Price Target

$64.75
106.08% Upside
According to the 18 analysts' twelve-month price targets for Centene, the average price target is $64.75. The highest price target for CNC is $89.00, while the lowest price target for CNC is $33.00. The average price target represents a forecasted upside of 106.08% from the current price of $31.42.
Get the Latest News and Ratings for CNC and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Centene and its competitors.

Sign Up

CNC Analyst Ratings Over Time

TypeCurrent Forecast
7/12/24 to 7/12/25
1 Month Ago
6/12/24 to 6/12/25
3 Months Ago
4/13/24 to 4/13/25
1 Year Ago
7/13/23 to 7/12/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
9 Buy rating(s)
9 Buy rating(s)
6 Buy rating(s)
Hold
12 Hold rating(s)
7 Hold rating(s)
7 Hold rating(s)
9 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$64.75$77.71$80.85$86.00
Forecasted Upside106.08% Upside40.30% Upside26.68% Upside26.73% Upside
Consensus Rating
Hold
Moderate Buy
Moderate Buy
Hold

CNC Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CNC Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Centene Stock vs. The Competition

TypeCenteneMedical CompaniesS&P 500
Consensus Rating Score
2.33
2.80
2.54
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside106.08% Upside8,597.75% Upside10.52% Upside
News Sentiment Rating
Neutral News

See Recent CNC News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/11/2025Mizuho
3 of 5 stars
Ann Hynes
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetNeutral ➝ Neutral$71.00 ➝ $40.00+26.10%
7/10/2025Morgan Stanley
3 of 5 stars
Ricky Goldwasser
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Equal Weight$70.00 ➝ $33.00
7/2/2025Bank of America
4 of 5 stars
Kevin Fischbeck
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetNeutral ➝ Neutral$65.00 ➝ $52.00+38.73%
7/2/2025Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Mok
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetEqual Weight ➝ Equal Weight$65.00 ➝ $45.00+20.05%
7/2/2025Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Sarah James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOverweight ➝ Overweight$90.00 ➝ $65.00+14.68%
7/2/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
John Stansel
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Neutral$75.00 ➝ $48.00-15.31%
7/2/2025UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A.J. Rice
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$80.00 ➝ $45.00-20.61%
4/29/2025Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
David Windley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetHold ➝ Hold$64.00 ➝ $61.00+2.98%
4/29/2025Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Cassorla
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
4/15/2025Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Michael Ha
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetNeutral ➝ Neutral$71.00 ➝ $69.00+9.63%
2/14/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Stephen Baxter
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOverweight ➝ Overweight$76.00 ➝ $72.00+26.47%
2/6/2025Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Staszak
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
12/13/2024Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight ➝ Equal Weight$75.00 ➝ $73.00+22.09%
12/13/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$89.00 ➝ $84.00+42.45%
12/13/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$95.00 ➝ $85.00+46.55%
10/30/2024Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$96.00 ➝ $88.00+42.19%
8/2/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Hold$82.00 ➝ $87.00+11.80%
7/31/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$80.00 ➝ $89.00+14.68%
5/30/2024Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Ha
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
7/12/2023Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Peer Perform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 06:19 AM ET.


Should I Buy Centene Stock? CNC Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, July 11, 2025. Please send any questions or comments about these Centene pros and cons to contact@marketbeat.com.

Centene
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Centene Co.:

  • The stock has shown potential for upside, with recent price targets suggesting a possible increase from its current price, which is around $31.70.
  • Analysts have issued a mix of ratings, with several maintaining a "hold" or "buy" rating, indicating confidence in the stock's stability and potential for recovery.
  • Centene Co. has a relatively low price-to-earnings (P/E) ratio, suggesting that the stock may be undervalued compared to its earnings, which could attract value investors.
  • The company has a solid market capitalization, indicating a strong presence in the healthcare sector, which can provide a level of security for investors.
  • Recent analyst reports have highlighted the company's resilience and ability to adapt, which may bode well for long-term growth prospects.

Centene
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Centene Co. for these reasons:

  • Recent downgrades from analysts have significantly lowered price targets, with some dropping to as low as $40.00, indicating a lack of confidence in short-term performance.
  • The stock has experienced considerable volatility, with a twelve-month high of $80.59 and a low of $31.49, suggesting uncertainty in its price stability.
  • Centene Co. has a high debt-to-equity ratio, which may raise concerns about its financial leverage and ability to manage debt effectively.
  • Market sentiment has been cautious, with many analysts recommending a "neutral" stance, reflecting uncertainty about the company's future performance.
  • Recent trading volumes have fluctuated, which could indicate a lack of investor interest or confidence in the stock's future prospects.

CNC Forecast - Frequently Asked Questions

According to the research reports of 18 Wall Street equities research analysts, the average twelve-month stock price forecast for Centene is $64.75, with a high forecast of $89.00 and a low forecast of $33.00.

18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Centene in the last twelve months. There are currently 12 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" CNC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CNC, but not buy additional shares or sell existing shares.

According to analysts, Centene's stock has a predicted upside of 106.08% based on their 12-month stock forecasts.

Over the previous 90 days, Centene's stock had 1 downgrade by analysts.

Analysts like Centene less than other "medical" companies. The consensus rating for Centene is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how CNC compares to other companies.


This page (NYSE:CNC) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners